Heron Therapeutics Launches New Private Equity Strategy to Diversify Investment Offerings

Heron Therapeutics Expands Investment Horizons with New Private Equity Strategy

Heron Therapeutics boldly ventures into the realm of private equity with the recent launch of a new investment strategy tailored for accredited investors and family offices. Announced on December 9, 2025, this initiative marks a significant expansion of Heron's alternative investments platform, which previously focused primarily on private credit offerings. The newly introduced private equity strategy provides access to a diversified portfolio of over 7,000 private companies, allowing investors to pursue long-term capital appreciation through collaboration with four seasoned fund managers. This strategic pivot demonstrates Heron's commitment to enhancing its investment offerings and catering to the evolving needs of its clientele.

The underlying funds within this private equity strategy have garnered an impressive average annualized return of 13.2% since their inception, even after accounting for management fees. The fund managers involved bring over 30 years of experience in the private equity sector, further solidifying the strategy's credibility and appeal. Mike Sall, CEO of Heron, emphasizes that this launch aligns with the company’s mission to democratize access to institutional-grade private market assets for individual investors. By offering a complementary strategy to their income-focused private credit investments, Heron aims to provide investors with robust opportunities for growth in a landscape that increasingly favors private equity over public markets.

The private equity market has reached a staggering valuation of over $9 trillion, with institutional investors allocating nearly 17% of their portfolios to this asset class. This growing trend underscores the attractiveness of private equity for individual accredited investors, who typically benefit from its historical outperformance compared to public equities. Heron's new private equity approach stands out by ensuring a seamless investing experience, which includes low minimum investments, a fully digital platform for easy transactions, consolidated tax reporting, and monthly subscriptions without the burden of multi-year lockups or capital calls. This strategic move positions Heron Therapeutics to capitalize on the burgeoning demand for diversified investment options that traditional markets may struggle to deliver.

In addition to its innovative private equity strategy, Heron’s commitment to providing streamlined investment solutions continues to resonate within the industry. By focusing on accessibility and investor-centric features, the company enhances its reputation as a forward-thinking player in the investment landscape. As Heron expands its offerings, it remains poised to attract a broader range of investors looking for alternatives to conventional investment avenues.

This strategic expansion into private equity reflects not only Heron's adaptability but also its understanding of current market dynamics and investor needs, setting a promising course for future growth and investor engagement.